Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4390808 | 0.94 | CNR1 (0.63) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1706666 | 0.92 | CNR1 (0.59) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1707291 | 0.92 | CNR1 (0.58) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1708396 | 0.88 | CNR1 (0.55) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL12191448 | 0.88 | CNR1 (0.48) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1707014 | 0.87 | CNR1 (0.64) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1756047 | 0.84 | CNR1 (0.56) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1708384 | 0.84 | CNR1 (0.54) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1706937 | 0.84 | CNR1 (0.54) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1706936 | 0.84 | CNR1 (0.54) | CNR1CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094705-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2012-04-18 | — | — | EP | disclosed |
| EP-2094705-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2012-04-18 | — | — | EP | disclosed |
| US-8030306-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100029656-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| WO-2008076810-A9 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029656-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, ARRB1 | CNR1 1/4885CYP2C9 746/4885CYP2C19 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.